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Abstract 
Physico-chemical, metabolic and hormonal theories 
regarding the pathogenesis of calcium oxalate nephro-
lithiasis do not sufficiently explain many features of this 
disease. The recent findings of an abnormally faster 
oxalate self-exchange and higher phosphorylation of 
band 3 in erythrocytes of idiopathic calcium oxalate 
stone formers suggest the hypothesis that nephrolithiasis 
may be a cellular disease, characterized by a defect in 
the function of the anion-exchange. The cellular 
anomaly seems genetically controlled. Band 3 anion 
exchanger function seems to be biochemically regulated 
through modulation of band 3 phosphorylation, which 
depends on cyclic AMP- and phospholipid-sensitive 
Ca2+ independent protein kinases. In this light, a 
reduced glycosaminoglycan concentration in the 
erythrocyte membranes of stone formers might play a 
role, as these molecules exert a strong inhibitory effects 
on band 3 phosphorylation and anion transport in vitro 
and in vivo. An in vivo trial was performed in which 
stone formers were administered glycosaminoglycans 
orally. A reduction in oxalate excretion, and oxalate 
renal clearance, and a simultaneous correction of the 
abnormal RBC oxalate flux and band 3 phosphorylation 
were observed. These data suggest the existence of a 
link between the erythrocyte abnormality and oxalate 
transport by the kidney and gut. 
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Introduction 
No less than 76 % of all kidney stones are made up 
of calcium oxalate (CaOx), and in 80% of the cases we 
are dealing with idiopathic forms of nephrolithiasis 
(Nordin et al., 1979). The physico-chemical theory of 
lithogenesis, explains stone formation by the precipita-
tion, growth and crystalline aggregation of several litho-
genic salts in the urine, and has contributed greatly to 
the understanding of the complex problem of the etiolo-
gy and pathogenesis of calcium urolithiasis (Fleisch, 
1978). Calcium oxalate and calcium phosphate are po-
tentially the most insoluble lithogenic salts under the 
ionic conditions normally present in urine; indeed, their 
supersaturation level even in the urine of non-stone 
forming subjects is very close to the point of sponta-
neous precipitation. 
The risk of forming CaOx stones is determined by 
the degree of calcium salt supersaturation, and the activi-
ty level of factors stabilizing (inhibitors) and destabiliz-
ing (promoters) their nucleation, crystal-growth and 
crystal-aggregation (Robertson et al., 1978). Idiopathic 
calcium nephrolithiasis (ICN) is currently interpreted as 
the consequence of an imbalance between these factors 
(Robertson et al., 1978; Baggio et al., 1982). 
The principal determinants of urine calcium salt sat-
uration are urine pH, calcium and oxalate excretion, and 
diuresis. Most studies addressed the role of calcium ion 
in promoting ICN. In the last _decade, however, the 
pathogenetic role of oxalate has been revaluated in the 
light of physico-chemical considerations and clinical 
findings (see for a review Smith, 1988). Indeed minim-
al changes in urinary oxalate concentration produced in-
crease in CaOx supersaturation than equal variations in 
calcium concentration (Finlayson, 1974). Moreover, se-
verity of disease and entity of crystalluria were well cor-
related with oxaluria, rather than calciuria (Robertson 
and Peacock, 1980). 
While urine supersaturation clearly is necessary for 
stone formation, it does not seem the sole prerequisite, 
as urine supersaturation by the main lithogenic salts is 
frequently present even in non-stone forming subjects 
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(Robertson et al., 1968). These results led to the con-
cept that there exist substances in urine that can inhibit 
crystal nucleation, growth and aggregation; citrate, pyro-
phosphate, magnesium, glycoproteins and glycosamino-
glycans (GAGs) seem endowed with such activity; in re-
ference to GAGs, an inhibitory effect on CaOx crystal 
growth in vitro was proven (Kok et al., 1988; Gjaldbaek 
1982), and an excretion deficit in stone formers was 
documented (Robertson et al., 1978; Baggio et al., 
1982; Caudarella et al., 1983; Martelli et al., 1985; 
Baggio et al., 1987a; Nikkilii, 1989; Michelacci et al., 
1989), although not unanimously (Samuell, 1981; Hesse 
et al., 1986; Fellstrom et al., 1986; Hwang et al., 
1988). Moreover in nephrolithiasis, not only a quantita-
tive, but also a qualitative defect exists, because the 
degree of GAG sulfation is higher than normal (Foye et 
al., 1976; Fellstrom et al., 1986). 
The causes that may lead to an imbalance between 
saturation and urinary inhibition might reside in sys-
temic, metabolic, or renal anomalies. The latter are cer-
tainly very important in the idiopathic forms of nephro-
lithiasis; in fact, primary tubular loss of calcium (Pak, 
1979), reduced urinary citrate excretion due in part to 
partial defect in renal acidification (Minisola et al., 
1989), and altered excretion of renal tubular epithelium 
constituents, such as renal enzymes (Baggio et al., 
1983a), glycosaminoglycans, and Thamm-Horsfall gly-
coprotein (Gambaro et al., 1984) have been often report-
ed. Several studies addressed whether the tubular anom-
alies were primitive and therefore pathogenetically im-
portant, or only a consequence of stone formation, but 
no firm conclusion was reached (Jaeger et al., 1986); 
nonetheless, there is evidence that at least some anom-
alies are primitive in nature. 
From this brief digression, it appears evident that 
ICN has been viewed above all as a physico-chemical 
problem, or a metabolic and hormonal disorder. While 
studies based on these approaches have been of great im-
portance, several aspects are still unexplained, leading to 
the recent concept that cellular anomalies might be deter-
minant in ICN pathogenesis (Baggio et al., 1984a, 
1986a). 
In this review, we will discuss findings in support 
of this theory, and their possible clinical and pharmaco-
logical applications. 
The Theory of Cellular Anomalies as the 
Pathogenetic Factor 
In developing a cellular hypothesis of this disease, 
we considered that the co-existence of familial occur-
rence, tubular disease associated with ICN, and anoma-
lies in the systemic handling of oxalate might suggest the 
presence of a generalized cellular defect. Other obser-
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vations buttressed this idea, in particular, the change in 
the epidemiology and clinical pattern of urinary stone 
disease (Robertson and Peacock, 1982), and the obvious 
impact of environment, as seen in hypertension, in 
which a possible primary cellular alteration is highly 
suspected; moreover, further clinical and physico-chemi-
cal observations of the effect of even small increase in 
urinary oxalate concentration on the lithogenetic process. 
Alterations in Cellular Transport of Oxalate 
The study of oxalate self-exchange through the 
erythrocyte membrane under conditions of equilibrium 
supported the working hypothesis. Anomalous trans-
membrane flux in red blood cells (RBC) was present in 
70-80% of the subjects studied (Baggio et al., 1986a). 
Other workers corroborated this finding (Jenkins et al., 
1988; Narula et al., 1988). As this disorder is not pre-
sent in secondary forms of calcium nephrolithiasis, it 
seems characteristic of ICN, and moreover, genetically 
controlled, with a mendelian-type segregation. The sim-
plest explanation is that the increased erythrocyte flux 
has the features of an autosomal, monogenic dominant 
trait with complete penetration, and variable expression. 
However, a polygenic inheritance with frequent and 
linked genes, and two different thresholds (one for 
increased flux, and the other for nephrolithiasis) cannot 
be ruled out. 
In the families we studied, this anomaly was also 
present in non stone-forming subjects. Moreover ne-
phrolithiasis, which was detected only in subjects with 
the anomaly, appeared more frequently in males, and 
only after the second decade of life. These observations 
further stressed the impact of environmental (diet, etc.) 
and sex-linked factors. 
We then tried to clarify the relationships between al-
tered cellular oxalate flux and ICN; that is, whether we 
were dealing with a pathogenetic or a casual association, 
and if the anomaly could constitute a risk marker for 
ICN. Follow-up studies in five families revealed five 
new cases after five years of observation, and these oc-
curred only in subjects with the cellular anomaly (unpub-
lished). This finding suggested that this cellular trait 
constitutes a risk marker of the disease. 
The use of erythrocyte anion channel-inhibiting sub-
stances showed that the anomalous oxalate transport was 
related to an alteration in band 3 cell protein function 
(Baggio et al., 1984b). Proteins immunologically corre-
lated with band 3 red cell protein were also detected in 
the gut and kidney. Moreover, it was demonstrated that 
band 3 renal protein in the basolateral membrane of in-
tercalated alpha cells of the collecting duct is encoded by 
the same gene that encodes band 3 erythrocyte protein 
(Demuth et al., 1986; Brosius et al., 1989; Kudricki and 
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Shull, 1989). These cells are deputized to proton secre-
tion (Steinmetz, 1986), and band 3 protein has a very 
important role due to its anion transporting function, 
particularly chloride and bicarbonate (Steinmetz, 1986). 
On the basis of these biological considerations, we 
investigated the presence of functional alterations in the 
gut and kidney in subjects with the red cell anomaly. 
We found that a more rapid intestinal oxalate absorption 
(Baggio et al., 1986a) and abnormalities in distal acidi-
fication (Gambaro et al., 1988) were associated with in-
creased erythrocytic flux. The former naturally may 
translate into urinary oxalate excretory peaks, and hence 
into peaks of urinary supersaturation for calcium oxa-
late; the latter have been repeatedly observed in ICN, 
and are generally considered a consequence of the ne-
phropathy (Jaeger et al., 1986), despite their possible 
pathogenetic role in calcium-phosphate lithiasis, and def-
inite causal role in overt type 1 renal tubular acidosis. 
However, low distal tubular proton secretion, as seen in 
this type of acidification defect, opposes our theory of a 
hyperfunctioning anion carrier because, if the same RBC 
defect is also present in alpha intercalated cells, proton 
secretion would be favored, giving rise to more acidic 
urine. However, studies in this sense in ICN patients 
without acidification defects, showed that bicarbonate 
infusion caused a significantly higher urine to blood 
PCO2 gradient in subjects with higher RBC oxalate self-
exchange, compared to those with normal oxalate flux. 
We reasoned that if the anion exchanger were hyperac-
tive, it would have been more sensitive to peritubular bi-
carbonate concentration, one of the main factors control-
ling the activity of the basolateral anion exchanger of 
alpha intercalated cells (Breyer et al., 1986). These two 
apparently contradictory results are still puzzling us. 
Although further study is mandatory, some very prelimi-
nary data suggest a redundant proton secretion, at least 
by some CaOx stone formers. In these patients, the pro-
duction of a more acidic urine after an acid load could 
facilitate CaOx stone formation. In other words, there-
fore, not only an incomplete form of distal renal tubular 
acidosis might exist in some stone formers, but also a 
higher than normal proton excretion in another subset of 
patients. 
Alterations in the Red Blood Cell Anion Carrier 
The biochemical basis of the anomalous erythrocyte 
oxalate flux might reside in an altered phosphorylation 
state of the membrane proteins, and in particular band 3, 
which is the known anion carrier in red blood cells 
(Cabantchik et al., 1978). Compared to controls, in 
fact, phosphate incorporation is greater in the erythro-
cytic membranes of stone formers (Baggio et al., 1986b, 
1987b). 
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The hypothesis of a causal link between the two cel-
lular abnormalities is suggestive, and supported by evi-
dence that drugs, such as stilbenes, which bind covalent-
ly with the protein and inhibit its phosphorylation, in a 
parallel manner also reduce cell transport of oxalate 
(Baggio et al., 1984b), as well as the observation that 
both anomalies seem dependent upon the intracellular en-
ergy level, as ATP depletion induces a reduction in both 
oxalate flux and band 3 phosphorylation (Baggio et al., 
1986b). However, it is still debated whether anion 
transport modulation involves phosphorylation of band 
3, and other membrane proteins (Bursaux et al., 1984; 
Clari et al., 1990; Yannoukakos et al., 1991). Prelimi-
nary results from our laboratory evidenced a close rela-
tionship between the level of band 3 phosphorylation and 
its function as an anion exchanger. In fact, anion trans-
port was unmodified by agents mediating cyclic AMP-, 
or phospholipid-sensitive Ca2+ -dependent protein ki-
nases that are responsible for phosphorylation of some 
red cell membrane proteins, other than band 3 (Raval 
and Allan, 1985). This is the case in adenylcyclase acti-
vation by forskolin, and in endogenous diacylglycerol in-
crease following RBC incubation with phospholipase C 
and Ca2+, as well as the activation of protein kinase C 
by phorbol myristate acetate or short incubation with 
oleil-2-acetyl-rac-glycerol (OAG). On the other hand, 
agents able to modify the phosphorylation state of the 
erythrocyte anion carrier, such as low molecular weight 
heparin or longer incubation with OAG, also induce 
changes in oxalate transmembrane self-exchange. These 
findings also suggest that cyclic AMP- and phospholipid-
sensitive Ca2 + -independent protein kinases are critical 
modulators of band 3 function. Thus, our current views 
on the possible mechanisms involved in the origin of the 
erythrocytic anomalies associated with ICN suggest a 
primary structural defect in band 3 protein might be 
proposed, even though it is extremely unlikely that a 
primitive defect involves simultaneously two proteins, 
band 3 and 2 which are both abnormally phosphorylated 
in stone formers (Baggio et al., 1986b). However, we 
are addressing this aspect by evaluating the possible ex-
istence of a linkage between the increased RBC oxalate 
flux and chromosome 17, where band 3 gene is located 
(Lux et al., 1989). Our first attempt failed because the 
large family we studied was not sufficiently informative 
in reference to the probe employed. 
The hypothesis of an imbalance between AMP- and 
Ca2+ -insensitive protein kinases, and phosphatases 
seems more interesting, and in this way it might be 
more easily explained the link between RBC band 3 
anomalies, and the oxalate carriers in the proximal tu-
bule and in gut that have only structural and functional 
homologies with band 3 protein, and are encoded by dif-
ferent genes (Alper et al., 1987). Despite their differ-
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ences, these anion/oxalate carriers might depend upon 
the same regulatory mechanisms, thus explaining parallel 
derangements in their function. The putative imbalance 
in kinase activities might involve both the enzymes 
themselves, or modulating effectors of their activities. 
This idea is supported by our finding of abnormally low 
GAG level in erythrocytes from stone formers (Baggio 
et al., 1990), as these molecules exert inhibitory effects 
on band 3 phosphorylation and anion transport in vitro 
and in vivo (see below) (Baggio et al., 1988, 1990, 
1991a, 1991b). 
Thus, the possibility exists that transport of other 
ions also dependent upon the same mechanism would be 
abnormal. Indeed, we recently observed a higher urate 
self-exchange in ICN patients (Gambaro et al., 1990), 
even though inconstantly associated with the faster oxa-
late transport, so raising the possibility that exchange is 
specific for a certain ion, at least at some step of the 
transport and/or its regulatory mechanism. Alternative-
ly, a different hierarchy of affinity for carrier between 
anions could explain these results. 
Clinical and Pharmacological Considerations 
That some cell alterations may be considered a pos-
sible primary metabolic defect in ICN opens new per-
spectives for defining the risk of nephrolithiasis, and 
preventing recurrences pharmacologically. Concerning 
the former, risk markers for nephrolithiasis are not yet 
available at present. In fact, the anomalies associated 
with this disease (hypercalciuria, hyperoxaluria, low 
urinary citrate levels, defect in crystal agglomeration 
inhibiting activity in urine, etc.) have been proposed as 
risk markers only on the basis of case-control investiga-
tions between stone-formers and non-stone-formers, 
without being tested in prospective studies to verify their 
predictivity of the disease. On the other hand, based on 
our family follow-up study (see above), increased red 
blood cell oxalate flux might be a means to detect sub-
jects at risk of ICN. This would make it possible to es-
tablish dietary or other types of regimes in these sub-
jects, in order to prevent the disease from acting on 
other non-genetic risk factors. However, as the impact 
of environment on ICN and its possible relationship with 
the cellular anomaly is not yet sufficiently understood, 
further study is needed before this type of application 
can be suggested. 
In reference to pharmacologic prophylaxis, drugs 
able to modulate the observed cellular abnormalities 
could modify urinary physico-chemical conditions, and 
hence the natural history of the disease. Several mole-
cules have been studied in this sense, and fmdings were 
favorable regarding cellular activity, and effect on uri-
nary physico-chemical balance in many cases. Nonethe-
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less, how they would influence the natural history of 
nephrolithiasis is not known, as long-term prospective 
studies are not yet available. 
Drugs capable of favorably modifying the natural 
history of the disease, such as hydrochlorothiazide 
(Maschio et al., 1982), are undoubtedly able to correct 
oxalate self-exchange in red blood cells (Baggio et al., 
1986a), and change band 3 protein phosphorylation ki-
netics (Baggio et al., 1987b). Other drugs, such as 
amiloride (Baggio et al., 1987c; Clari et al., 1986) and 
the calcium antagonists (Baggio et al., 1986c; Gambaro 
et al., 1987) were able to normalize erythrocyte oxalate 
flux, and the latter also induced a change in the urinary 
excretion of calcium. 
Glycosaminoglycans are also able to influence red 
cell oxalate flux (Baggio et al., 1988; 199 la), and 
probably exert this effect through their powerful modu-
lating action on membrane kinases (Hathaway et al., 
1980; Lecomte and Boivin, 1981; Meggio et al., 1982; 
Boivin et al., 1985), which are deputized to the phos-
phorylation of the anion carrier. 
GI ycosaminogl ycans are considered important inhibi-
tors of lithogenesis; their urinary excretion is frequently 
reduced in ICN patients; a decreased erythrocyte GAG 
content has also been reported in ICN patients (Baggio 
et al., 1990), and their synthesis in the fibroblasts of 
stone-forming subjects seems reduced (Caudarella et al., 
1987). Since it is possible that an anomaly which is pre-
sent in one cellular line might also be present in other 
cell compartments, the pathogenetic role of glycosamino-
glycans in ICN might be more complex than previously 
thought. 
In vitro, these drugs and in particular the low mo-
lecular weight heparins, heparan sulfate and dermatan 
sulfate, albeit with different efficacy, are able to inhibit 
band 3 protein phosphorylation, as well as red blood cell 
oxalate flux at concentration of2.5 µglml (Baggio et al., 
1988), which is much lower than that needed to inhibit 
protein kinase C (200 µg/1) (Wise et al., 1982). Our 
findings are consistent with data from Hathaway et al. 
(1980), Lecomte and Boivin (1981), and Clari and 
Ferrari (1983) demonstrating that casein kinase is in-
hibited by heparin at concentrations of a few µg/1 or 
ng/1, which are much lower than that needed for protein 
kinase C. This was one more reason to exclude the pro-
tein kinase C-dependent pathway from the pathogenesis 
of the cellular abnormality observed in nephrolithiasis. 
To explore the possible clinical application of these 
drngs in the prevention of stone relapses, and also to 
obtain deeper insights into the pathogenesis of ICN, as 
well as establish a definitive pathogenetic link between 
the RBC oxalate anomaly and nephrolithiasis, we 
searched for a link between the erythrocyte abnormality 
and oxalate transport by the kidney and gut. 
Cellular Anomalies in Nephrolithiasis 
Our rationale was that if we were able to correct the 
RBC oxalate anomaly in vivo, oxalate transporters in the 
kidney and in gut might respond similarly, leading to 
changes in urinary excretion and clearance of oxalate, 
since these carriers have molecular and functional simi-
larities with erythrocyte band 3 (Alper et al., 1987). 
GAGs seemed a good candidate to verify this hypothe-
sis, as they are able to correct both oxalate self-exchange 
and band 3 phosphorylation in erythrocytes. 
For clinical use, oral administration is, of course, 
preferable, but this route for GAGs is currently still con-
sidered unreliable; it is generally thought that they are 
catabolized at the intestinal epithelial level to mono-
saccharides devoid of any pharmacological activity. 
This is not true; Larsen et al. (1986) demonstrated the 
presence of mainly oligo-, di- and mono-saccharides, 
and to a minor extent octa-and tetra-saccharides in the 
blood following a single oral dose of 35S-heparin or 3H-
heparin. At the same time an anti-factor Xa appeared, 
probably due to the larger heparin fragments. These 
workers also reported that oral administration of heparin 
in the presence of cortisone induced a systemic anti-
angiogenic effect (Folkman et al., 1983). Norman et al. 
(1985) found that the oral administration of a synthetic 
GAG, sodium pentosan polysulphate, was followed by 
a slight but significant increase in the negative zeta 
potential in urine, a measure of the polyanionic inhibito-
ry activity of crystallization. Intestinal absorption of 
intact or large fragments of heparin and dermatan sul-
phate was recently demonstrated (Jaques et al., 1991, 
Dawes et al., 1989). 
We employed a mixture of GAGs extracted from 
animals approved for human use in Italy, which is com-
posed of two GAGs that are highly active in vitro on 
RBC abnormalities (70% a heparin-like fraction, and 
30% dermatan sulphate). Pharmacokinetic studies dis-
closed that almost 50 % of this drug is absorbed after 
oral administration, and 25 % is excreted unmodified by 
the kidney (unpublished). In view of these findings, we 
may estimate that at least 15 mg/day of the drug are ab-
sorbed unaltered through the intestinal epithelium (daily 
dose 60 mg time 25 % ). If the distribution of this 
heparinoid is in the vascular space alone (approximately 
5 I), its plasma concentration would be about 3 mg/I 
which, based on our in vitro data is certainly sufficient 
to inhibit RBC oxalate flux up to 55 % , and RBC band 
3 phosphorylation up to 30 % . Indeed, following oral 
administration, this drug was effective on RBC anoma-
lies (Baggio et al., 1991a) and at the same time exerted 
a hypooxaluric action (Baggio et al., 1991b). 
Although this drug, following intra-venous adminis-
tration, was able to reduce renal oxalate clearance, its 
hypooxaluric effect under steady-state conditions, such 
as those of the 15 day trial, must also be necessarily due 
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to intestinal inhibition of dietary oxalate absorption 
(Baggio et al., 1991b). As glycosaminoglycans do not 
bind oxalate (Baggio et al., 1983b) we believe they act 
at the intestinal level with a mechanism similar to that 
most probably acting on the proximal tubular epithelium, 
that is by modifying the phosphorylation of band 3-relat-
ed transporters and, therefore, cellular oxalate flow. It 
cannot be ruled out that the hypooxaluric effect may be 
explained by a reduction in endogenous oxalate synthe-
sis, or oxalate precipitation in the body of oxalate as a 
calcium salt, but these hypotheses seem unlikely. 
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Discussion with Reviewers 
W. G. Robertson: If thiazides correct the oxalate trans-
port excess in the red cells from stone formers, why do 
they not reduce urinary oxalate excretion, since this 
would be anticipated from the authors' model? 
Authors: Our data show no relationship between 24 
hour urinary oxalate and the flux rate constant of the 
oxalate self-exchange in RBC. It seems that the differ-
ence between ICN patients with increased or normal 
oxalate flux lies in a different time course of oxaluria 
after oral challenge with oxalate. In fact, 8 hours after 
challenge, oxalate recovery from the urine is the same 
regardless of the presence or not of the RBC abnormali-
ty; however, subjects with increased RBC oxalate self-
exchange displayed a faster excretion of oxalate in the 
first 2-4 hours (Baggio et al., 1986a). It is true that 
thiazides were never shown to reduce urinary oxalate ex-
cretion, but we wonder if they cannot modify the time 
course of oxaluria after meals. 
B. Hesse: To what extent did urinary oxalate excretion 
decrease during treatment with GAGs, and was the de-
crease significantly correlated with reduced erythrocyte 
oxalate self-exchange and band 3 protein phosphoryla-
tion? 
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Authors: 15 day oral treatment with GAGs promoted 
a reduction in urinary oxalate of 25 % , in erythrocyte 
oxalate self-exchange of 35 % , and in band 3 phosphory-
lation of 24% (Baggio et al., 1991b). The three varia-
bles were not statistically correlated. 
Reviewer V: Have GAGs decreased stone formation in 
patients with ICN? 
Authors: To our knowledge there is only one open 
clinical study in which the effect of GAGs on stone re-
lapses was evaluated. Danielson et al. (1988) reported 
that in 96 frequent relapsing stone forming patients 
(some of whom had enteric disorders), pentosan polysul-
phate, 400 mg/daily, decreased the disease activity dur-
ing a mean treatment time of 22 months. Pentosan poly-
sulphate, a synthetic GAG, was orally administered at a 
very high dosage capable of increasing the inhibition of 
calcium oxalate crystal growth in urine. No effect was 
observed on oxalate excretion. We have no experience 
with this drug on RBC oxalate self-exchange, and unfor-
tunately it is not possible to match this drug with the 
animal extractive GAG used in our study due to their 
different chemical structure, and to the different bio-
availability (pentosan polysulphate has a very low oral 
bioavailability, 0.5-1 % ). 
M. Akbarieh: The authors suggested that red blood cell 
anomaly is a risk marker of ICN. How can the authors 
explain this hypothesis, and how it might be tested? 
Authors: When we published our family studies on the 
genetics of the RBC anomaly in 1986, we observed that 
not all the subjects presenting the anomaly had passed 
stones (Baggio et al., 1986a). After a 5 year follow-up, 
5 of those subjects became stone-formers. It is remarka-
ble that only those with the RBC anomaly formed uri-
nary stones; we believe that this is a clear demonstration 
that abnormal oxalate self-exchange in erythrocytes is a 
marker of the risk to become a stone-former. Of 
course, to strengthen this conviction, more families must 
be studied with a longer follow-up, and more insights 
into the physiopathological meaning of the cellular 
anomaly in terms of nephrolithiasis must be gained. 
